Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Seres Therapeutics (MCRB) just unveiled an update.
Seres, SPN, and Bacthera AG have agreed to terminate their existing Manufacturing Agreement as part of a new Purchase Agreement. This decision comes with the stipulation that Seres will assign the agreement to SPN, who will then pay Bacthera AG to settle any outstanding liabilities. This move coincides with SPN’s private placement of shares, asserting their status as an accredited investor and confirming the shares are for personal investment, not for resale or distribution in violation of the Securities Act.
See more insights into MCRB stock on TipRanks’ Stock Analysis page.